Related Technologies - University of Pittsburgh

Search text

About 24 results

(0.11 seconds)

A Novel Treatment for Metastatic Prostate Cancer

06044

• Treatment of metastatic castration resistant prostate cancer.

Current therapeutic approaches for PC target the production or the physiological pathways involving androgens crucial for the growth of prostate cells.

University of Pittsburgh researchers have identified a novel class of chemical compounds to treat the currently uncurable metastatic castration-resistant prostate cancer (mCRPC).

Pharm-Pharmaceutical Science

2022-06-01

Compounds Targeting Androgen Receptor to Treat Castration-Resistant Prostate Cancer

02501

Castration-resistant prostate cancer (CRPC) is currently incurable and makes prostate cancer the second most common cause of cancer death among men in the United States.

· Lead compounds are effective against all tested AR-positive prostate cancer cell lines.

Castration-resistant prostate cancer (CRPC) is currently incurable and makes prostate cancer the second most common cause of cancer death among men in the United States.

2011-06-10

Borylated Esters and Acetals as Cancer Prodrugs

06731

In cancer cells the boronate group is readily removed by elevated concentrations of endogenous per-oxide releasing the therapeutic agent and selectively targeting cancer cells.

Novel prodrugs have been synthesized which are converted to a cytotoxic agent in the presence of high levels of endogenous peroxide levels routinely found in cancer cells and hypoxic environments, and could lead to a new selective treatment for cancer.

Further studies showed that high sensitivity of cancer cells to the prodrug correlated to endogenous peroxide cells.

Therapeutic Modality

Small Molecule

Oncology

Small molecule Life Science

Paul Floreancig

Chemistry

2024-04-29

Novel Senotherapeutic Agents for Cancer Therapy